
Ceribell Inc (CBLL) Stock Forecast & Price Target
Ceribell Inc (CBLL) Analyst Ratings
Bulls say
CeriBell Inc is poised for significant growth, projecting revenues of $87 million to $89 million in 2025, reflecting an anticipated annual increase of 33% to 36%, largely due to strong seasonal performance and strategic investments in its salesforce. The company's innovative Ceribell System, which combines portable hardware with AI algorithms for rapid neurological diagnostics, positions it to capitalize on expanding market opportunities in various healthcare settings, including VA hospitals and pediatric populations. Additionally, CeriBell benefits from a high gross margin of approximately 80%, a dual revenue stream business model, and a robust financial strategy aimed at achieving cash-flow breakeven, all of which contribute to a positive long-term outlook.
Bears say
CeriBell Inc. is currently experiencing significant financial challenges, reporting a net loss of $40 million in the most recent year and lacking free cash flow positivity, which casts doubt on its operational sustainability. The company faces additional margin pressures due to tariffs and legal expenses, compounded by uncertainties that could arise from geopolitical risks, particularly concerning its reliance on Chinese imports. Furthermore, a low market capitalization combined with a history of operating losses and a limited penetration rate in existing accounts highlights the company's aggressive risk profile and vulnerability to potential downturns in customer demand and competitive dynamics.
This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.
Ceribell Inc (CBLL) Analyst Forecast & Price Prediction
Start investing in Ceribell Inc (CBLL)
Order type
Buy in
Order amount
Est. shares
0 shares